학술논문

Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope
Document Type
Report
Source
Cell. August 19, 2021, Vol. 184 Issue 17, 4414
Subject
Disease transmission
Monoclonal antibodies
Viral antigens
Immunotherapy
Nervous system diseases
Antigenic determinants
Arthritis
Biological products
Encephalitis
Medical schools
Medical colleges
Language
English
ISSN
0092-8674
Abstract
Keywords alphavirus; antibody; protection; immunity; Fc effector; inhiibtion; pathogenesis; mice; encephalitis; arthritis Highlights * Monoclonal antibodies from CHIKV-seropositive donors are pan-alphavirus reactive * DC2.112 and DC2.315 map to a conserved epitope in the alphavirus E1 protein * DC2.112 and DC2.315 protect in vivo against infection by multiple alphaviruses * E1 protein is a target for pan-alphavirus therapeutics and possible vaccine design Summary Alphaviruses are emerging, mosquito-transmitted pathogens that cause musculoskeletal and neurological disease in humans. Although neutralizing antibodies that inhibit individual alphaviruses have been described, broadly reactive antibodies that protect against both arthritogenic and encephalitic alphaviruses have not been reported. Here, we identify DC2.112 and DC2.315, two pan-protective yet poorly neutralizing human monoclonal antibodies (mAbs) that avidly bind to viral antigen on the surface of cells infected with arthritogenic and encephalitic alphaviruses. These mAbs engage a conserved epitope in domain II of the E1 protein proximal to and within the fusion peptide. Treatment with DC2.112 or DC2.315 protects mice against infection by both arthritogenic (chikungunya and Mayaro) and encephalitic (Venezuelan, Eastern, and Western equine encephalitis) alphaviruses through multiple mechanisms, including inhibition of viral egress and monocyte-dependent Fc effector functions. These findings define a conserved epitope recognized by weakly neutralizing yet protective antibodies that could be targeted for pan-alphavirus immunotherapy and vaccine design.